Abstract-The role of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) in the maintenance of cardiac homeostasis still remains controversial. This study was designed to evaluate the role of cardiomyocyte-specific PTEN in the maintenance of cardiac homeostasis and the underlying mechanisms involved with a focus on autophagy, an evolutionarily conserved pathway for protein degradation. Cardiomyocyte-specific PTEN (flox/flox) /α-myosin heavy chain Cre mice, henceforth referred to as CM-PTENKO, were generated by crossing the floxed PTEN mice with α-myosin heavy chain Cre mice driven by a Cre recombinase promoter. The adult PTEN −/− mice displayed the phenotype of established hypertrophic cardiomyopathy, including unfavorable geometric, functional, and histological changes. Furthermore, cardiomyocyte-specific PTEN knockout mice exhibited increased cardiac mammalian target of rapamycin although suppressed autophagy. Treatment with rapamycin (2 mg/kg per day, IP), an inhibitor of mammalian target of rapamycin, for 1 month effectively reversed the established hypertrophic cardiomyopathy in CM-PTENKO mice. With rapamycin treatment, autophagy activity was significantly restored in the heart of CM-PTENKO mice. Taken together, our results demonstrate an essential role for cardiomyocyte PTEN in maintaining cardiac homeostasis under physiological condition. Cardiomyocyte-specific deletion of PTEN results in the development of hypertrophic cardiomyopathy possibly through a mechanism associated with mammalian target of rapamycin hyperactivation and autophagy suppression. studies have consolidated an indispensable role for autophagy in the maintenance of cardiac geometry and function under both physiological and pathological conditions. 22, 23 It has been shown that basal levels of autophagy are essential for cardiac homeostasis under physiological conditions. Atg (autophagyrelated gene) 5 deficiency results in loss of amino acids and ATP availability in the heart, thus leading to neonatal death.
C ardiovascular disease is one of the leading causes of morbidity and mortality in the United States and other developed countries.
1,2 Among such, hypertrophic cardiomyopathy, a genetically predisposed heart disease, contributes to the increased prevalence of heart failure and sudden cardiac death (or resuscitated cardiac arrest) in young adults. 3 Ample evidence has confirmed the cause of hypertrophic cardiomyopathy mainly from mutations in genes encoding essential protein components of the sarcomere, namely β cardiac myosin heavy chain (MHC) and myosin binding protein C. 4 However, approximately one fourth of hypertrophic cardiomyopathy may be attributed to mutations in other genes, most of which unidentified. 5 Recent evidence has depicted an indispensable although conflicting role for phosphatase and tensin homolog deleted from chromosome 10 (PTEN) in the maintenance of cardiac homeostasis. 6, 7 PTEN depletion was shown to facilitate the development of cardiac hypertrophy accompanied with compromised cardiomyocyte contractile function although the underlying mechanism remains essentially elusive. 6 However, loss of PTEN was demonstrated to be cardioprotective against pressure overload-induced cardiac hypertrophy and heart failure. 8, 9 As a downstream target of PTEN, mammalian target of rapamycin (mTOR) activity has been demonstrated to be tightly regulated by PTEN through tuberous sclerosis complex (TSC). 10 PTEN deficiency is capable of promoting hyperactivation of mTOR in animal models and patients. 11, 12 It is widely conceived that mTOR orchestrates cardiac hypertrophy given its role in governing protein synthesis. 13 Aberrant activation of mTOR has been shown to contribute to the onset and development of cardiac hypertrophy. [14] [15] [16] More importantly, inhibition of mTOR using rapamycin has shown some promise in the reversal of established cardiac hypertrophy in animal models. 5, [15] [16] [17] [18] In addition to regulation of protein synthesis, mTOR also serves as the primary suppresser for autophagy, an evolutionarily conserved pathway for the maintenance of intracellular homeostasis. 19, 20 Macroautophagy, herein referred to as autophagy, is a catabolic process involved in recycling intracellular proteins and organelles and generation of ATP for energy homeostasis. 21 In the past decade, accumulating studies have consolidated an indispensable role for autophagy in the maintenance of cardiac geometry and function under both physiological and pathological conditions. 22, 23 It has been shown that basal levels of autophagy are essential for cardiac homeostasis under physiological conditions. Atg (autophagyrelated gene) 5 deficiency results in loss of amino acids and ATP availability in the heart, thus leading to neonatal death. 24 The indispensable role for basal autophagy in cardiac homeostasis is further consolidated by the fact that conditional knockout of Atg5 or Atg7 gene prompts cardiac hypertrophy and dampens cardiac function. 25 To this end, the present study was designed to examine the role of autophagy, a downstream component of the PTEN-mTOR signaling cascade, in cardiomyocyte-specific deletion of PTEN-induced cardiac anomalies and more importantly the therapeutic potential of autophagy induction using rapamycin in PTEN deletioninduced cardiac defect, if any.
Materials and Methods

Generation of Cardiomyocyte-Specific PTEN Knockout Mice
All animal procedures performed in this study were approved by the Animal Care and Use Committee at the University of Wyoming (Laramie, WY) and were in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Cardiomyocyte-specific PTEN (flox/flox) /α-MHC Cre mice, henceforth referred to as CM-PTENKO, were generated by crossing the floxed PTEN mice with α-MHC Cre mice driven by a Cre recombinase promoter (Jackson Laboratories, Stock No. 009074, Bar Harbor, ME). The wild-type (WT) PTEN (−/−), heterozygous PTEN (+/−), and floxed PTEN (+/+) alleles were analyzed using polymerase chain reaction with tail DNA when mice were 4-week-old. The Cre recombinase transgene was analyzed using polymerase chain reaction as previously described. 26 Only PTEN (flox/flox) littermates negative for α-MHC Cre were used as WT. WT and CM PTEN −/− mice with or without rapamycin Figure 1 . Generation of cardiomyocyte-specific phosphatase and tensin homolog deleted from chromosome 10 (PTEN) knockout mice. A, Representative polymerase chain reaction gel bands from mice containing floxed PTEN and the α-myosin heavy chain (α-MHC) Cre transgene. B, Representative gel blots depicting protein levels of PTEN in heart, skeletal (Sk) muscle, brain, and liver; protein tyrosine phosphatase 1B (PTP1B) and phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase type 2 (SHIP2) in heart from CM-PTENKO mice. GAPDH was used as the loading control. C-H, Quantification of PTEN expression in the heart, Sk muscle, brain, and liver; PTP1B and SHIP2 in heart from CM-PTENKO mice. 
Results
Generation of CM-PTENKO Mice
To generate CM-PTENKO mice, homozygous floxed PTEN mice were bred with the α-MHC Cre transgenic mice. Mice were born with few notable defects and survived to adulthood. The offspring were genotyped and screened for the recombinant allele using conventional polymerase chain reaction analysis of tail genomic DNA ( Figure 1A ). Western blot analysis further confirmed that majority of PTEN protein was depleted in the heart but not in any other organs from CM-PTENKO mice ( Figure 1B 
CM-PTENKO Causes Hypertrophic Cardiomyopathy in Mice
Although cardiomyocyte-specific knockout of PTEN did not affect survival in mice, it prompted a hypertrophic . Concordantly, the heart-to-body weight ratio was significantly greater in CM-PTENKO mice compared with the WT mice ( Figure 2F and 2G). Histological analysis further confirmed that cardiomyocyte-specific knockout of PTEN dramatically increased the cross-sectional area of cardiomyocytes ( Figure 2H and 2I). Cardiomyocyte-specific knockout of PTEN-facilitated cardiac hypertrophy was substantiated by a dramatic increase in mRNA expression of cardiac fetal genes, including atrial natriuretic peptide, brain natriuretic peptide, and β-MHC, in CM-PTENKO mouse hearts ( Figure 2J-2L ).
In addition, we noted overt interstitial fibrosis in the heart of CM-PTENKO mice ( Figure 2M and 2N ). Furthermore, our immune-confocal microscopy analysis demonstrated that deletion of PTEN dramatically triggered cardiomyocyte apoptosis characterized by the TUNEL (in situ terminal dUTP nick end-labeling)-positive nuclei in cardiomyocytes stained with Desmin ( Figure 2O and 2P). Consistently, protein level of the antiapoptotic marker Bcl-2 was significantly decreased, whereas the proapoptotic marker Bax was dramatically increased in CM-PTENKO mouse hearts ( Figure 3A-3C ). Next, we examined mitogen-activated protein kinase signaling cascade, considering its essential role in the development of pathological hypertrophic cardiomyopathy. 27 Neither extracellular signal-regulated kinase 1/2 nor jun N-terminal kinase 1/2 was significantly activated in response to cardiomyocytespecific knockout of PTEN ( Figure 3A , 3D, 3E, 3F, 3G, 3H, 3I, 3J, and 3K), reminiscent of the previous finding. 7 To further consolidate a role of PTEN in the regulation of cardiomyocyte function, mechanical properties were evaluated in cardiomyocytes isolated from CM-PTENKO and WT mice. Although loss of PTEN failed to significantly increase cell length in cardiomyocytes, it dramatically dampened cardiomyocyte contractile function, as evidenced by decreased velocity of shortening and relengthening (±dL/dt), peak shortening, and prolonged time-to-90% relengthening without affecting time-to-peak shortening ( Figure S1A -S1F in the online-only Data Supplement). To further explore the possible mechanism(s) behind impaired contractile dysfunction in PTEN −/− cardiomyocytes, intracellular Ca 2+ handling was evaluated. Our data revealed that loss of PTEN failed -ATPase type 2a was significantly decreased, whereas phospholamban was markedly increased in CM-PTENKO mouse hearts ( Figure 3A , 3L, and 3M).
PTEN Deficiency in Cardiomyocytes Induces Akt-mTOR Signaling Pathway Activation
Earlier study has indicated hyperactivated cardiac PKB (protein kinase B)/Akt signaling in the muscle-specific knockout of PTEN en route to cardiac hypertrophy. 6 Coincidently, Akt phosphorylation, but not pan protein expression, was found to be elevated in the heart of CM-PTENKO mice ( Figure 4A-4C) . Next, myocardial TSC2, a direct downstream target of Akt, was evaluated. Our data revealed that PTEN deletion dramatically increased myocardial TSC2 phosphorylation/activation, without affecting the pan protein expression of TSC2 ( Figure 4A , 4D, and 4E). Subsequently, myocardial mTOR, which is directly regulated by TSC, was hyperactivated in CM-PTENKO heart, as manifested by elevated phosphorylation of mTOR and pS6K ( Figure 4A , 4F, and 4H). Pan protein expression of mTOR and S6K was unaffected by cardiomyocyte-specific deletion of PTEN ( Figure 4A , 4G, and 4I).
Cardiomyocyte-Specific Depletion of PTEN Inhibits Myocardial Autophagy Pathway
Given that mTOR serves as the primary inhibitory regulator of autophagy, we evaluated autophagy in the heart from WT and CM-PTENKO mice. As an important mediator governing initiation of autophagy, the activity of uncoordinated 51-like kinase 1 (Ulk1) was suppressed by mTOR through Ser 757 phosphorylation. 28 As expected, our data displayed that loss of PTEN markedly increased the phosphorylation of Ulk1 at Ser 757 in the heart ( Figure 5A and 5B). Total protein level of Ulk1 was unaffected by PTEN knockout (Figure 5A and 5C) .
The formation of microtubule-associated protein light chain 3 B type II, a mammalian homolog of yeast Atg8, is one of the most widely used markers for autophagosomes. 29 A dramatic decrease in light chain 3 B type II was observed in the heart from CM-PTENKO mice ( Figure 5A , 5E, and 5F). Because the decrease in autophagosome formation may have resulted from either a decrease in the generation of autophagosome (inhibited initiation) or an increase of autophagosome degradation (facilitated clearance), 29 we next examined the level of p62, a selective autophagy cargo adaptor protein. 30 A significant accumulation of p62 was noted in the heart of CM-PTENKO mice ( Figure 5A and 5G). Furthermore, our data revealed that myocardial levels of Beclin1 and Atg7 were downregulated in CM-PTENKO mice ( Figure 5A, 5H, and 5I) . Taken together, these findings favor the notion that cardiomyocyte-specific knockout of PTEN suppresses myocardial autophagy activity (dampened initiation and degradation).
Rapamycin Rescues Hypertrophic Cardiomyopathy in CM-PTENKO Mice
To further consolidate a role of autophagy in cardiomyocyte-specific PTEN deletion-induced cardiac anomalies, rapamycin, a widely used specific mTOR complex 1 inhibitor, 31 was administered to promote autophagy (2 mg/ kg per day, IP for 30 days). 15, 16 Our data revealed that chronic treatment with rapamycin dramatically improved cardiac geometry and function in CM-PTENKO mice without affecting cardiac geometry and function in WT mice ( Figure 6A-6E ). Rapamycin treatment reversed cardiac hypertrophy developed in CM-PTENKO mice without affecting cardiac geometry in WT mice ( Figure 6F and 6G) . To further confirm that rapamycin ameliorated loss of PTEN-induced cardiac hypertrophy, cross-sectional area in cardiomyocytes was evaluated. Our results indicated that rapamycin dramatically attenuated the cross-sectional area of cardiomyocytes in CM-PTENKO mice without affecting that in WT mice Figure 6H and 6I) . Next, our real-time polymerase chain reaction data revealed that although rapamycin did not affect myocardial fetal gene expression in WT mouse hearts, it significantly alleviated increased mRNA expression of atrial natriuretic peptide, brain natriuretic peptide, and β-MHC in CM-PTENKO mouse hearts ( Figure 6J-6L ). In addition, Masson trichrome staining was examined to evaluate interstitial fibrosis. Loss of PTEN-induced cardiac interstitial fibrosis was significantly attenuated by the treatment with rapamycin. Rapamycin treatment did not affect cardiac fibrosis in WT mice ( Figure 6M and 6N) .
Consistent with echocardiographic findings, our results showed that rapamycin treatment effectively rescued PTEN deletion-induced cardiomyocyte contractile dysfunction ( Figure S2A-S2F) . Furthermore, analysis of intracellular Ca 
Rapamycin Restores Myocardial mTOR-Mediated Autophagy Activity in CM-PTENKO Mice
To examine the possible mechanisms underlying the cardioprotective effect of rapamycin in CM-PTENKO mice, myocardial autophagy was evaluated using Western blot analysis. Our data revealed that treatment with rapamycin significantly inhibited the activity of mTOR pathway in the heart from WT and CM-PTENKO mice, as evidenced by reduced levels of phosphor-mTOR and phosphor-S6K ( Figure 7A, 7B, and 7D ). Not surprisingly, inhibition of mTOR promoted basal autophagy in the heart from WT mice, as evidenced by increased expression of Atg7, Beclin1, and light chain 3 B type II, and decreased accumulation of phosphor-Ulk1 and p62 ( Figure 7A , 7F, 7G, 7H, 7I, 7J, 7K, 7L, and 7M). Importantly, on rapamycin treatment, the inhibited autophagy pathway in the heart from CM-PTENKO mice was dramatically ameliorated. 
Restoration of Cardiac Autophagy With Rapamycin Treatment Attenuated Myocardial Apoptosis in CM-PTENKO mice
We went on to examine the effect of rapamycin treatment on apoptosis in the heart using TUNEL staining and Western blot analysis. As shown in Figure 8 , the loss of PTEN significantly promoted cardiomyocyte apoptosis as evaluated by both TUNEL staining and Western blot analysis, the effects of which were mitigated rapamycin. Rapamycin treatment did not affect cardiomyocyte apoptosis by itself.
Discussion
The salient findings from our current study suggested that cardiomyocyte-specific PTEN deletion triggers pronounced hypertrophic cardiomyopathy (echocardiographic remodeling and dampened myocardial function) probably through inhibition of basal myocardial autophagy. In particular, cardiomyocyte-specific knockout of PTEN significantly increases cardiomyocyte cross-sectional area, fetal gene expression, interstitial fibrosis, and apoptosis in the heart. Furthermore, cardiomyocyte-specific PTEN deletion compromises cardiomyocyte contractile function, intracellular Ca 2+ handling, and intracellular Ca 2+ regulatory protein expression. Our study depicted a role of mTOR-mediated autophagy in the indispensable action of PTEN in the maintenance of cardiac homeostasis. More importantly, our results provided the proof-of-concept evidence for mTOR-dependent autophagy in PTEN-governed cardiac homeostasis as treatment with rapamycin, a specific inhibitor for mTOR, restored hypertrophic cardiomyopathy and myocardial autophagy in CM-PTENKO mice. Last but not least, treatment with rapamycin significantly attenuated cardiomyocyte apoptosis in the heart of CM-PTENKO mice.
Earlier evidence has depicted an indispensable role for PTEN in the maintenance of cardiac homeostasis and myocardial contractile function. 6 However, the precise role for PTEN in the regulation of cardiac geometry and function still remains controversial. 6, 7 However, recent evidence from Oudit et al showed that deletion of PTEN may be beneficial against pressure overload-induced heart failure probably through preserving myocardial angiogenesis and metabolic genes. 7 In these earlier studies, the muscle-specific conditional PTEN knockout mice were used to elucidate the role of PTEN in the heart. 6, 7 To better understand the role of PTEN in the maintenance of cardiac homeostasis, we generated a cardiomyocyte-specific PTEN knockout mouse model. Reminiscent of previous reports, 6 our data demonstrated that loss of PTEN prompts development of hypertrophic cardiomyopathy and cardiomyocyte contractile dysfunction. 6, 7 Cardiomyocyte-specific loss of PTEN leads to significantly increased LV wall thickness, LV end systolic diameter, and LV end diastolic diameter and reduced fractional shortening. Consistently, cardiomyocyte-specific PTEN deletion increases cardiomyocyte cross-sectional area, interstitial fibrosis, and cardiomyocyte apoptosis. More importantly, loss of PTEN triggers cardiomyocyte intracellular Ca 2+ handling and contractile anomalies, reminiscent of earlier report. 6 Our observation further revealed hyperactivated myocardial PI3K (phosphatidylinositide 3-kinases)-Akt signaling cascade with cardiomyocyte-specific loss of PTEN, as manifested by Akt phosphorylation. Our data further depicted an essential role of mTOR in the development of hypertrophic cardiomyopathy in CM-PTENKO mice. In our hands, basal mTOR activity is overtly elevated in the heart from CM-PTENKO mice. As the direct upstream regulator of mTOR, TSC2 phosphorylation is also significantly elevated in the heart of CM-PTENKO mice. It has been shown that mTOR is tightly regulated by the TSC1/2 complex, whereas loss of TSC1/2 activity (through phosphorylation) directly results in mTOR hyperactivation. 13 The activity of mTOR is influenced by various molecular modulators, among which Akt acts as the primary drive. 10 Through phosphorylation of TSC2, Akt interrupts the ability of TSC2 to inhibit mTOR signaling, leading to phosphorylation of mTOR. 10, 32 Accumulating studies have suggested that mTOR is a key regulator for cell size in various organs including heart. 5, [15] [16] [17] 33 Loss of TOR has been shown to reduce cell size in mosaic Drosophila. 33 In various models of cardiac hypertrophy, the activity of mTOR is found to be significantly elevated. 16, 19 More importantly, treatment with rapamycin, a specific mTOR inhibitor, may effectively reverse cardiac hypertrophy induced by various triggers including pressure overload, adrenergic receptor agonist phenylephrine, and genetic mutation. 5, [15] [16] [17] Observation from our present study favored a unique role for mTOR in PTEN depletion-induced hypertrophic cardiomyopathy. A pivotal role of mTOR is appreciated not only in the process of protein synthesis but also in autophagy. 11, 31, 34 Autophagy is an evolutionarily conserved pathway involved in bulk degradation of intracellular organelles and proteins. Over the past decades, the role of autophagy in the governance of cardiac homeostasis under physiological and pathophysiological conditions has been extensively explored. Under physiological conditions, it is conceived that basal autophagy prevents abnormal protein aggregation and degrades long-lived proteins and organelles, providing free amino acids and fatty acids for the maintenance of cellular ATP levels and anabolic pathways. 35 The indispensable role of basal autophagy in the maintenance of cardiac geometry and function is highly appreciated by development of cardiac hypertrophy and dysfunction on inactivation of either Atg5 or Atg7 autophagy gene. 25, 36 Furthermore, neonatal mice deficient in Atg5 displayed less availability of amino acid and ATP in the heart and plasma, thus provoking embryonic lethality within a day after birth. 24 Our data revealed suppressed myocardial autophagy in hearts from CM-PTENKO mice in an mTOR-dependent manner. Treatment with rapamycin rescued myocardial autophagy in the heart of CM-PTENKO mice. Through forming a ternary complex with the FK506-binding protein 12 and the FRB (FKBP12-rapamycin-binding) domain of mTOR, rapamycin is capable of inhibiting the activity of mTOR complex 1.
37 mTOR complex 1 is an inhibitor of autophagy probably through phosphorylation of the Atg1-Ulk1 complex. 28 Treatment with rapamycin has been widely used for autophagy induction through inhibiting mTOR activity in various organ systems including brain, liver, and heart. 11, 31, 38 Autophagy induction by rapamycin has been shown to be an avenue in the therapeutic remedies against cardiac dysfunction under several pathological conditions such as aging and LMNA (lamin A and C) cardiomyopathy. 38, 39 PTEN was previously demonstrated to function as a mechanosensing signal transducer for myosin II in Dictyostelium cells. 40 Although it is beyond the scope of our current study, other possible mechanisms such as mechanosensing may not be excluded at this time.
In conclusion, our study provides evidence for the first time that mTOR complex 1-mediated autophagy suppression contributes to PTEN deletion-triggered hypertrophic cardiomyopathy. This is supported by the observation that myocardial autophagy is suppressed in the heart of CM-PTENKO mice and that treatment with rapamycin restored myocardial autophagy and rescued hypertrophic cardiomyopathy. Although it is somewhat premature to consolidate a unique role of autophagy in the cardiomyocyte-specific PTEN deletion-induced hypertrophic cardiomyopathy, our results should shed some lights toward a better understanding for the role of PTEN in the maintenance of myocardial geometry and function. Human studies have confirmed the presence of PTEN haploinsufficiency. 41 Findings from our current study suggest that individuals with PTEN deficiency may be prone to the development of hypertrophic cardiomyopathy. More importantly, rapalogs, derivatives of rapamycin, are in clinical practice for treatment of human diseases. 42 Our findings have shown promise in clinical therapeutic strategy using rapamycin in the management of hypertrophic cardiomyopathy possibly resulting from PTEN mutations.
Perspectives
The findings from our study revealed overt hypertrophic cardiomyopathy in adult mice with cardiomyocyte-specific knockout of PTEN. PTEN deficiency increases cardiac mTOR and suppresses autophagy. Treatment with rapamycin, a specific mTOR inhibitor and an autophagy inducer, effectively rescued the established hypertrophic cardiomyopathy in CM-PTENKO mice. Currently, derivatives of rapamycin are used in clinical practice for treatment of human diseases. Human studies have indicated the presence of PTEN haploinsufficiency. It is likely that stimulation of autophagy with rapamycin may possess potential clinical use in the treatment of hypertrophic cardiomyopathy possibly resulting from PTEN mutations.
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